David Andorsky, MD Medical Oncologist, Associate Chair, US Oncology Research Group, Rocky Mountain Cancer Centers shares the results and findings for idelalisib in patients with relapsed or refractory follicular lymphoma.
Idelalisib in Relapsed or Refractory Follicular Lymphoma
